• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4832873)   Today's Articles (5695)
For: Caraco Y, Blotnick S, Muszkat M. CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study. Clin Pharmacol Ther 2007;83:460-70. [PMID: 17851566 DOI: 10.1038/sj.clpt.6100316] [Citation(s) in RCA: 275] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Number Cited by Other Article(s)
151
Optimization of anticoagulation with warfarin for stroke prevention: pharmacogenetic considerations. Am J Ther 2012;18:e55-66. [PMID: 20335792 DOI: 10.1097/mjt.0b013e3181cea0cd] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
152
Wang M, Lang X, Cui S, Fei K, Zou L, Cao J, Wang L, Zhang S, Wu X, Wang Y, Ji Q. Clinical application of pharmacogenetic-based warfarin-dosing algorithm in patients of Han nationality after rheumatic valve replacement: a randomized and controlled trial. Int J Med Sci 2012;9:472-9. [PMID: 22927772 PMCID: PMC3427951 DOI: 10.7150/ijms.4637] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/23/2012] [Accepted: 07/24/2012] [Indexed: 12/02/2022]  Open
153
Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. ADVANCES IN PHARMACOLOGY (SAN DIEGO, CALIF.) 2012;63:137-67. [PMID: 22776641 DOI: 10.1016/b978-0-12-398339-8.00004-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
154
Amici S, Paciaroni M, Agnelli G, Caso V. Gene-drug interaction in stroke. Stroke Res Treat 2011;2011:212485. [PMID: 22135769 PMCID: PMC3216369 DOI: 10.4061/2011/212485] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2011] [Revised: 07/05/2011] [Accepted: 09/02/2011] [Indexed: 01/09/2023]  Open
155
Perlstein TS, Goldhaber SZ, Nelson K, Joshi V, Morgan TV, Lesko LJ, Lee JY, Gobburu J, Schoenfeld D, Kucherlapati R, Freeman MW, Creager MA. The Creating an Optimal Warfarin Nomogram (CROWN) Study. Thromb Haemost 2011;107:59-68. [PMID: 22116191 DOI: 10.1160/th11-08-0568] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2011] [Accepted: 10/23/2011] [Indexed: 11/05/2022]
156
Factor VII R353Q genetic polymorphism is associated with altered warfarin sensitivity among CYP2C9 *1/*1 carriers. Eur J Clin Pharmacol 2011;68:617-27. [DOI: 10.1007/s00228-011-1143-z] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Accepted: 10/07/2011] [Indexed: 10/15/2022]
157
Roden DM, Johnson JA, Kimmel SE, Krauss RM, Medina MW, Shuldiner A, Wilke RA. Cardiovascular pharmacogenomics. Circ Res 2011;109:807-20. [PMID: 21921273 DOI: 10.1161/circresaha.110.230995] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
158
Cavallari LH, Jeong H, Bress A. Role of cytochrome P450 genotype in the steps toward personalized drug therapy. PHARMACOGENOMICS & PERSONALIZED MEDICINE 2011;4:123-36. [PMID: 23226058 PMCID: PMC3513224 DOI: 10.2147/pgpm.s15497] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/04/2011] [Indexed: 12/19/2022]
159
Xu H, Jiang M, Oetjens M, Bowton EA, Ramirez AH, Jeff JM, Basford MA, Pulley JM, Cowan JD, Wang X, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC. Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin. J Am Med Inform Assoc 2011;18:387-91. [PMID: 21672908 DOI: 10.1136/amiajnl-2011-000208] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]  Open
160
Lötsch J, Geisslinger G. Pharmacogenetics of new analgesics. Br J Pharmacol 2011;163:447-60. [PMID: 20942817 DOI: 10.1111/j.1476-5381.2010.01074.x] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]  Open
161
Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, Anderson JL, Kimmel SE, Lee MTM, Pirmohamed M, Wadelius M, Klein TE, Altman RB. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther 2011;90:625-9. [PMID: 21900891 PMCID: PMC3187550 DOI: 10.1038/clpt.2011.185] [Citation(s) in RCA: 472] [Impact Index Per Article: 33.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
162
Pharmacogenetics and cost-effectiveness analysis: a two-way street. Drug Discov Today 2011;16:873-7. [DOI: 10.1016/j.drudis.2011.08.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Revised: 08/23/2011] [Accepted: 08/24/2011] [Indexed: 11/23/2022]
163
Degoma EM, Rivera G, Lilly SM, Usman MHU, Mohler ER. Personalized vascular medicine: individualizing drug therapy. Vasc Med 2011;16:391-404. [PMID: 22003003 PMCID: PMC3761360 DOI: 10.1177/1358863x11422251] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
164
Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther 2011;90:519-31. [PMID: 21918509 PMCID: PMC3190669 DOI: 10.1038/clpt.2011.179] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
165
Attitudes of health care professionals toward pharmacogenetic testing. Mol Diagn Ther 2011;15:115-22. [PMID: 21623646 DOI: 10.1007/bf03256401] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
166
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 2011;118:3163-71. [DOI: 10.1182/blood-2011-03-345173] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]  Open
167
Howard R, Leathart JBS, French DJ, Krishan E, Kohnke H, Wadelius M, van Schie R, Verhoef T, Maitland-van der Zee AH, Daly AK, Barallon R. Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon® probes. Clin Chim Acta 2011;412:2063-9. [PMID: 21827742 DOI: 10.1016/j.cca.2011.07.013] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 07/09/2011] [Indexed: 02/03/2023]
168
Ferraldeschi R, Newman WG. Pharmacogenetics and pharmacogenomics: a clinical reality. Ann Clin Biochem 2011;48:410-7. [DOI: 10.1258/acb.2011.011084] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
169
Cappola TP, Margulies KB. Functional genomics applied to cardiovascular medicine. Circulation 2011;124:87-94. [PMID: 21730321 PMCID: PMC3138215 DOI: 10.1161/circulationaha.111.027300] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
170
Wu CL, Raja SN. Treatment of acute postoperative pain. Lancet 2011;377:2215-25. [PMID: 21704871 DOI: 10.1016/s0140-6736(11)60245-6] [Citation(s) in RCA: 356] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
171
Anticoagulant therapy: warfarin sensitivity genotyping closer to clinical practice. Nat Rev Cardiol 2011;7:549-50. [PMID: 20865027 DOI: 10.1038/nrcardio.2010.126] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
172
Musunuru K. Current Role of Pharmacogenomics in Cardiovascular Medicine. CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE 2011;13:302-12. [DOI: 10.1007/s11936-011-0129-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
173
A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 2011;13:509-18. [PMID: 21423021 DOI: 10.1097/gim.0b013e31820ad77d] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
174
Springer JA, Iannotti NV, Kane MD, Haynes K, Sprague JE. Pharmacogenomics training using an instructional software system. AMERICAN JOURNAL OF PHARMACEUTICAL EDUCATION 2011;75:32. [PMID: 21519421 PMCID: PMC3073107 DOI: 10.5688/ajpe75232] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/25/2010] [Accepted: 11/15/2010] [Indexed: 05/09/2023]
175
Finkelman BS, Gage BF, Johnson JA, Brensinger CM, Kimmel SE. Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol 2011;57:612-8. [PMID: 21272753 DOI: 10.1016/j.jacc.2010.08.643] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2010] [Revised: 07/16/2010] [Accepted: 08/24/2010] [Indexed: 01/21/2023]
176
Wright DFB, Duffull SB. Development of a bayesian forecasting method for warfarin dose individualization. Pharm Res 2011;28:1100-11. [PMID: 21301936 DOI: 10.1007/s11095-011-0369-x] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2010] [Accepted: 01/10/2011] [Indexed: 12/17/2022]
177
You JHS. Pharmacoeconomic evaluation of warfarin pharmacogenomics. Expert Opin Pharmacother 2011;12:435-41. [DOI: 10.1517/14656566.2011.521153] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
178
Verhoef TI, Redekop WK, Darba J, Geitona M, Hughes DA, Siebert U, de Boer A, Maitland-van der Zee AH, Barallon R, Briz M, Daly A, Haschke-Becher E, Kamali F, Kirchheiner J, Manolopoulos VG, Pirmohamed M, Rosendaal FR, van Schie RMF, Wadelius M. A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics 2011;11:989-1002. [PMID: 20602617 DOI: 10.2217/pgs.10.74] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
179
Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, He F, Zhou RN, Zheng QS, Zhao LZ. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol 2011;70:234-40. [PMID: 20653676 DOI: 10.1111/j.1365-2125.2010.03698.x] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
180
Stack G. Pathology consultation on warfarin pharmacogenetic testing. Am J Clin Pathol 2011;135:13-9. [PMID: 21173120 DOI: 10.1309/ajcpao82otnpublw] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]  Open
181
Rosenberg G, Marshall LS, Caraco Y. The Neuroprotective Agent DP-b99 Does Not Interact with S-warfarin In Vivo Despite Significant CYP2C9 Inhibition In Vitro. Basic Clin Pharmacol Toxicol 2010;108:289-92. [PMID: 21414144 DOI: 10.1111/j.1742-7843.2010.00654.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
182
Verhoef TI, Schalekamp T, Redekop WK, de Boer A, Maitland-van der Zee AH. Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. Expert Rev Pharmacoecon Outcomes Res 2010;10:375-8. [PMID: 20715914 DOI: 10.1586/erp.10.42] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
183
Pendleton RC, Rodgers GM, Hull RD. Established Venous Thromboembolism Therapies: Heparin, Low Molecular Weight Heparins, and Vitamin K Antagonists, with a Discussion of Heparin-Induced Thrombocytopenia. Clin Chest Med 2010;31:691-706. [DOI: 10.1016/j.ccm.2010.07.003] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
184
French B, Joo J, Geller NL, Kimmel SE, Rosenberg Y, Anderson JL, Gage BF, Johnson JA, Ellenberg JH. Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 2010;11:108. [PMID: 21083927 PMCID: PMC3000386 DOI: 10.1186/1745-6215-11-108] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2010] [Accepted: 11/17/2010] [Indexed: 11/16/2022]  Open
185
Donohue MM, Tirschwell DL. Implications of pharmacogenetic testing for patients taking warfarin or clopidogrel. Curr Neurol Neurosci Rep 2010;11:52-60. [PMID: 21046289 DOI: 10.1007/s11910-010-0157-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
186
Pirmohamed M. Acceptance of Biomarker-Based Tests for Application in Clinical Practice: Criteria and Obstacles. Clin Pharmacol Ther 2010;88:862-6. [DOI: 10.1038/clpt.2010.245] [Citation(s) in RCA: 53] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
187
Joo J, Geller NL, French B, Kimmel SE, Rosenberg Y, Ellenberg JH. Prospective alpha allocation in the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Clin Trials 2010;7:597-604. [PMID: 20693186 PMCID: PMC3111931 DOI: 10.1177/1740774510381285] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
188
Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet Genomics 2010;20:407-13. [PMID: 20442691 DOI: 10.1097/fpc.0b013e328338bac2] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
189
Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit 2010;32:338-45. [PMID: 20386359 DOI: 10.1097/ftd.0b013e3181d925bb] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
190
Cascorbi I. Safe and effective medicines for all: is personalized medicine the answer? Expert Rev Clin Pharmacol 2010;3:627-37. [PMID: 22111745 DOI: 10.1586/ecp.10.36] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
191
Predicting warfarin dose. Curr Opin Pulm Med 2010;16:426-31. [DOI: 10.1097/mcp.0b013e32833b1c6c] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
192
Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria. Clin Chim Acta 2010;411:1375-7. [DOI: 10.1016/j.cca.2010.04.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2010] [Revised: 04/09/2010] [Accepted: 04/13/2010] [Indexed: 11/23/2022]
193
Will there be a role for genotyping in warfarin therapy? Curr Opin Hematol 2010;17:439-43. [DOI: 10.1097/moh.0b013e32833c06b3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
194
Thornburg CD, Jones E, Bomgaars L, Gage BF. Pediatric warfarin practice and pharmacogenetic testing. Thromb Res 2010;126:e144-6. [DOI: 10.1016/j.thromres.2009.12.022] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Revised: 11/23/2009] [Accepted: 12/30/2009] [Indexed: 11/28/2022]
195
Squassina A, Manchia M, Manolopoulos VG, Artac M, Lappa-Manakou C, Karkabouna S, Mitropoulos K, Zompo MD, Patrinos GP. Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice. Pharmacogenomics 2010;11:1149-67. [DOI: 10.2217/pgs.10.97] [Citation(s) in RCA: 106] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]  Open
196
The long and winding road to warfarin pharmacogenetic testing. J Am Coll Cardiol 2010;55:2813-5. [PMID: 20579536 DOI: 10.1016/j.jacc.2010.04.006] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2010] [Revised: 04/01/2010] [Accepted: 04/06/2010] [Indexed: 11/21/2022]
197
Lötsch J, Geisslinger G. A critical appraisal of human genotyping for pain therapy. Trends Pharmacol Sci 2010;31:312-7. [DOI: 10.1016/j.tips.2010.04.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2009] [Revised: 04/07/2010] [Accepted: 04/08/2010] [Indexed: 01/08/2023]
198
Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics 2010;11:493-6. [PMID: 20350128 DOI: 10.2217/pgs.10.31] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]  Open
199
Cascorbi I. The promises of personalized medicine. Eur J Clin Pharmacol 2010;66:749-54. [PMID: 20563567 DOI: 10.1007/s00228-010-0858-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2010] [Accepted: 06/02/2010] [Indexed: 01/11/2023]
200
Muszkat M, Bialer O, Blotnick S, Adar L, Xie HG, Ufer M, Cascorbi I, Caraco Y. Effects of folic acid supplementation on the pharmacokinetics and anticoagulant effect of warfarin: an open-label, prospective study of long-term administration in adults. Clin Ther 2010;32:347-56. [PMID: 20206792 DOI: 10.1016/j.clinthera.2010.02.008] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/23/2009] [Indexed: 02/06/2023]
PrevPage 4 of 6 123456Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA